Prediabetes & CGM Coverage — What Health Insurers Actually Say | 2026

There's a particular moment that a lot of health-aware adults seem to share — the moment a lab result arrives that isn't alarming enough to feel urgent, but isn't clean enough to ignore. A fasting glucose of 103. An A1C of 5.8. Numbers that sit in the gray zone between normal and clinical concern, accompanied by a note from the doctor that says something like "worth watching" or "let's check again in six months."

And then the questions start. Not just about what the numbers mean, but about what they mean for insurance. Can this affect my premiums? Will my health plan cover a glucose monitor now? Does prediabetes count as a pre-existing condition? What about that wearable CGM I've been reading about — would that be covered?

These questions are reasonable, and they come from a genuinely confusing intersection: metabolic health data that's becoming more sophisticated and more accessible on one side, and a health insurance system that has its own arcane logic for determining what it covers and why on the other. This piece is a straightforward, non-promotional look at how these two worlds meet — what the general landscape of coverage looks like for people in the prediabetes zone, what questions commonly arise around monitoring tools, and what the difference is between coverage decisions and clinical ones.

What Prediabetes Means in General Terms

The word prediabetes is a clinical label applied to a specific range of blood glucose measurements — fasting glucose between 100 and 125 mg/dL, or A1C between 5.7% and 6.4% — that fall above the reference range considered normal but below the threshold used to diagnose type 2 diabetes. It's a position on a continuum, not a separate disease state. It describes a metabolic pattern, not a moment of failure.

What the research consistently shows is that prediabetes exists on a trajectory — and that trajectory can move in more than one direction. A meaningful proportion of people with prediabetes-range readings do go on to develop type 2 diabetes within years if metabolic patterns remain unchanged. A meaningful proportion return to normal glucose ranges without a diagnosis. Others remain in the prediabetes zone for extended periods, a kind of metabolic holding pattern that reflects neither progression nor regression.

The trajectory is shaped by the same overlapping factors that have been discussed in other pieces in this cluster: insulin sensitivity, visceral fat accumulation, inflammatory load, sleep quality, activity patterns, and the gradual, cumulative drift that characterizes long-horizon metabolic risk. Prediabetes, in this context, is most usefully understood not as an endpoint but as a signal — a measurable indicator that the metabolic system is running under more stress than the normal reference range reflects, and that the trajectory of that stress over coming years deserves attention.

This is also, it turns out, the framing that health insurance systems are slowly starting to adopt. The shift from viewing prediabetes as a pre-disease borderline toward viewing it as an early-trajectory signal with its own clinical management implications has been gradual — but it has real consequences for what coverage looks like.

The Prediabetes Population in the United States

The scale of prediabetes in the US is worth understanding, because it shapes the entire landscape of coverage conversations. Estimates from the CDC suggest that a substantial proportion of American adults — somewhere in the range of one in three — meet criteria for prediabetes, the majority of whom are unaware of it. That's a very large population sitting in the gray zone, many of them generating the same coverage and monitoring questions without necessarily having heard the word prediabetes until a recent lab visit.

The sheer prevalence is part of what makes the coverage question genuinely complicated for insurers. If screening for and monitoring prediabetes is interpreted as preventive care — intervening early to reduce the trajectory toward expensive chronic disease management — the actuarial math can look favorable. If it's categorized as managing an existing metabolic condition, different coverage rules and cost structures apply. Where exactly prediabetes sits in that classification affects everything from what tests are covered at zero cost to whether a CGM is considered medically necessary.

How the ACA Changed the Pre-Existing Condition Landscape

One of the most consequential changes to the US health insurance landscape in recent decades was the Affordable Care Act's prohibition on using pre-existing conditions to deny coverage or set premiums in the individual and small group markets. Before 2014, having prediabetes — or any metabolic condition noted in medical records — could result in coverage denial, higher premiums, or exclusion riders that specifically excluded diabetes-related care. That landscape changed substantially with the ACA's guaranteed issue and community rating provisions.

Under current ACA rules, health plans sold on the individual market and through employer small group plans cannot deny coverage or charge higher premiums based on health status, including prediabetes. This is a meaningful protection. A person who receives a prediabetes diagnosis today cannot, in the ACA-regulated market, be turned down for coverage or charged more for their plan on that basis.

The picture looks somewhat different for other insurance types. Life insurance and disability insurance, which operate outside ACA regulations, can and do consider metabolic health history in underwriting decisions. Short-term health plans — a category that expanded under regulatory changes in the intervening years — may also have different rules around pre-existing conditions depending on their structure and state regulations. And large self-insured employer plans, while generally prohibited from discriminating based on health status under ERISA and HIPAA rules, have their own complexities.

The practical takeaway for someone with a new prediabetes-range result is that ACA-compliant health insurance coverage — through an employer's group plan, through a marketplace plan, or through Medicaid — is not something they can be denied or penalized for based on that result alone. But that protection doesn't automatically extend to all insurance products or contexts, and the distinction between coverage eligibility and premium rating versus benefit coverage for specific services is a different question entirely.

Introducing the Coverage Clarity Spectrum

To make sense of the landscape of coverage questions that arise around prediabetes and metabolic monitoring, it helps to think through what might be called the Coverage Clarity Spectrum — a conceptual framework for organizing different types of coverage questions by how clearly the regulatory and clinical framework answers them, ranging from well-established coverage rights to genuinely ambiguous terrain.

At the high-clarity end of the spectrum: ACA protections against coverage denial based on prediabetes. These are legally established, well-documented, and not subject to meaningful insurer discretion in compliant markets. Clear.

Moving toward the middle: coverage for prediabetes screening and testing under the ACA's preventive care mandate. The ACA requires most health plans to cover certain preventive services at no cost to the enrollee — including screening for type 2 diabetes in adults with certain risk factors. Whether and how this covers ongoing monitoring of prediabetes rather than initial screening is where the clarity starts to blur. The specific services covered, and under what conditions, vary by plan and by how clinical guidelines have been interpreted by plan administrators.

At the lower-clarity end: coverage for continuous glucose monitors in people with prediabetes. This is currently the most genuinely contested terrain. CGM coverage is well-established for certain diabetic populations — particularly type 1 diabetes, where CGMs are recognized as standard of care. For people with prediabetes or type 2 diabetes managed without insulin, coverage is considerably more variable, plan-dependent, and subject to medical necessity determinations that differ across insurers.

The Coverage Clarity Spectrum helps explain why the same person asking about prediabetes and insurance might get a very different answer depending on which specific question they're asking. Some questions have clear, legally grounded answers. Others land in territory that requires direct conversation with a plan administrator, a primary care clinician, or both.

Questions People Ask Insurers About Monitoring

When people with prediabetes-range results start thinking about monitoring their glucose more closely, a predictable set of questions emerges. Understanding how health plans generally approach these questions helps set realistic expectations.

"Will my plan cover a continuous glucose monitor?" This is the most common question, and the honest answer is: it depends, significantly, on the plan. For people with an established diabetes diagnosis — particularly type 1, and increasingly type 2 on insulin — CGM coverage has become more standard across Medicare, many Medicaid programs, and private insurance plans. For people with prediabetes, coverage is less consistent. Some plans cover CGMs for prediabetes under specific conditions: documented medical necessity, a prescribing physician's recommendation, and sometimes evidence of risk factors beyond the glucose numbers alone. Others do not cover them for prediabetes at all under current benefit structures. Over-the-counter CGMs — cleared by the FDA in 2024 without prescription requirement — can be purchased out of pocket and may be eligible for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA), which is worth exploring as a coverage alternative.

"Does prediabetes count as a pre-existing condition that could affect my coverage?" Under ACA-compliant health insurance in the individual and small group markets: no, a prediabetes diagnosis cannot be used to deny coverage or increase premiums. Outside ACA-regulated markets — life insurance, disability insurance, some short-term health products — the answer is more complicated and varies by insurer and product type.

"Will getting a prediabetes diagnosis or CGM data on my record affect future insurance?" This question comes up more often than people might expect, and the anxiety behind it is understandable. For ACA-compliant health insurance, the regulatory protections are clear. For other insurance products, the picture is less clear, and this is genuinely a question worth discussing with an insurance broker or benefits advisor who understands the full product landscape — not something this educational piece is positioned to advise on for individual situations.

The Medical Necessity Determination — How It Works

The phrase "medical necessity" appears frequently in coverage conversations about CGMs for prediabetes, and it's worth understanding what that phrase actually means in practice — because it's where individual clinical circumstances meet insurance policy language.

Health plans determine coverage for specific services through a combination of clinical criteria (what conditions or diagnoses qualify), utilization management policies (how requests for coverage are reviewed), and benefit design (what's included in the plan at all). For a service like CGM, a plan's coverage policy might specify that CGMs are covered for enrollees with an ICD-10 diagnosis code for type 1 or type 2 diabetes who meet certain clinical criteria — and might not list prediabetes as a covered indication.

Medical necessity determinations are made by the plan, often through a prior authorization process in which a prescribing clinician submits clinical documentation supporting the need for a service. For prediabetes, a clinician might document insulin resistance, high glucose variability, significant cardiovascular risk factors, or other clinical context that argues for the value of continuous monitoring in a particular patient. Whether that documentation results in a coverage approval depends on the plan's specific policies — and those policies vary considerably across insurers, plan types, and states.

What this means practically is that coverage for CGM in prediabetes isn't universally yes or universally no — it's a case-by-case determination, and the outcome often depends on how the clinical case is documented, which plan the person has, and whether a prior authorization process is initiated at all.

How Blood Sugar Topics Come Up With Health Plans

Beyond the specific CGM coverage question, there are other ways that blood sugar and metabolic health topics intersect with health insurance interactions that are worth understanding.

Preventive care screenings are one. The ACA mandates that ACA-compliant health plans cover certain preventive services at no cost to the enrollee — no deductible, no copay. Among these services is diabetes screening for adults who meet certain risk criteria, as recommended by the United States Preventive Services Task Force (USPSTF). As of recent USPSTF guidelines, screening for prediabetes and type 2 diabetes is recommended for adults aged 35 to 70 who are overweight or obese, and most ACA-compliant plans cover this screening under the preventive care benefit. A standard fasting glucose or A1C test ordered as a preventive screening should, in most ACA-compliant plans, be covered without cost-sharing. However, if the same test is ordered to monitor an existing condition rather than as a screening, it may be coded and covered differently.

The billing and coding distinction is a practical one that catches people off guard. A blood draw ordered as a preventive screening versus one ordered to monitor an established prediabetes diagnosis may look clinically identical — same test, same tube of blood — but be coded under different diagnosis categories that trigger different coverage and cost-sharing rules. Understanding how a lab order is being coded can affect how much an enrollee pays out of pocket, and it's a reasonable question to raise with both a clinician and a plan's member services team.

Diabetes Prevention Programs (DPPs) are another intersection point. The CDC-recognized National Diabetes Prevention Program is a structured lifestyle intervention for people with prediabetes, and Medicare has covered it for eligible beneficiaries since 2018. Many private insurers have also begun covering DPPs as a preventive benefit, recognizing the health economics case for early intervention. For someone with a prediabetes-range result looking for covered support, a DPP referral is worth asking about — it's one of the more consistently available covered resources in this space.

The Difference Between Coverage Decisions and Clinical Advice

One of the most important distinctions for anyone navigating the intersection of metabolic health and insurance is understanding where the line sits between coverage decisions — what a health plan will pay for — and clinical decisions — what a clinician recommends based on individual health circumstances.

These two things frequently get conflated, and the conflation causes real confusion. A health plan's decision not to cover CGM for prediabetes doesn't mean a clinician hasn't recommended it, or that the monitoring wouldn't be valuable for a particular person. It means the plan has made an administrative determination, based on its coverage criteria, that this service doesn't meet its reimbursement threshold for this indication. That's a financial and administrative decision, not a clinical one.

The reverse is also true: coverage for a service doesn't constitute clinical endorsement for every individual who qualifies under coverage criteria. A plan might cover certain monitoring for prediabetes while a clinician might, for a particular patient, see no clinical reason to pursue it. Coverage is the floor of what's available, not a prescription for what everyone should pursue.

This distinction matters especially for the CGM conversation in non-diabetic and prediabetic populations, where the evidence base for clinical benefit is still developing. Research examining CGM use in people without diabetes — including a recent assessment from Mass General Brigham — has noted that while CGMs can provide interesting and awareness-building glucose data, the evidence for measurable long-term health improvement from CGM use in non-diabetic individuals is still limited. Coverage decisions and clinical recommendations in this space are both evolving, and both are worth discussing directly with a clinician rather than drawing conclusions from either insurance approval or denial alone.

Frequently Asked Questions

Can a prediabetes diagnosis affect my ability to get health insurance in the US?

Under ACA-compliant health insurance — marketplace plans, employer group plans that comply with ACA standards, and Medicaid — a prediabetes diagnosis cannot be used to deny coverage or increase premiums. The ACA's guaranteed issue and community rating provisions prohibit discrimination based on health status in these markets. Life insurance, disability insurance, and certain non-ACA health products operate under different rules and may consider metabolic health history in underwriting. The ACA protections apply specifically to regulated health insurance coverage.

Does health insurance cover CGM for prediabetes?

Coverage for CGMs in people with prediabetes varies considerably by plan and insurer. Medicare and many private plans have established coverage for CGMs in people with diagnosed diabetes, particularly type 1. For prediabetes, coverage is less consistent — some plans cover it under specific medical necessity criteria, others do not. Over-the-counter CGMs, cleared by the FDA without prescription requirements, can be purchased out of pocket and are generally eligible for payment through HSAs and FSAs. The coverage landscape for CGM in prediabetes is actively evolving as clinical guidelines and insurer policies respond to accumulating research.

What preventive services related to blood sugar are covered at no cost under the ACA?

ACA-compliant health plans are required to cover certain preventive services at no cost to enrollees, including diabetes screening for adults aged 35 to 70 who are overweight or obese — as recommended by the USPSTF. This typically covers a fasting glucose or A1C test when ordered as a preventive screening. The Diabetes Prevention Program (DPP), a structured lifestyle intervention for people with prediabetes, is covered by Medicare for eligible beneficiaries and increasingly by private insurers as a preventive benefit. Coverage details vary by plan, and confirming coverage before a service is provided is always advisable.

What is a medical necessity determination for CGM coverage?

A medical necessity determination is the process by which a health plan evaluates whether a requested service — such as a CGM — meets its coverage criteria for a specific clinical indication. Plans typically require documentation from a prescribing clinician supporting the clinical rationale for the service. For CGM coverage in prediabetes, this documentation might include evidence of insulin resistance, significant metabolic risk factors, or other clinical context. Coverage determinations are made by the plan based on its specific policies, and outcomes vary. Prior authorization is often required, and denials can sometimes be appealed with additional clinical documentation.

Does a prediabetes diagnosis appear in insurance records and affect future coverage?

In ACA-regulated health insurance markets, a prediabetes diagnosis in medical records cannot legally be used to deny coverage or charge higher premiums. Medical records are protected by HIPAA and are not directly accessible to insurance companies without specific authorization. However, when applying for life insurance or disability insurance — which operate under different regulatory frameworks than health insurance — applicants are typically asked to disclose medical history including metabolic conditions, and insurers may request access to medical records as part of underwriting. The implications vary by insurer and product type and are worth discussing with an insurance professional for individual circumstances.

What is the National Diabetes Prevention Program and who covers it?

The CDC-recognized National Diabetes Prevention Program (DPP) is a structured, evidence-based lifestyle intervention designed for adults with prediabetes. It typically involves 16 core sessions over the first year followed by ongoing monthly support, delivered by trained lifestyle coaches either in person or online. Medicare covers the DPP for eligible beneficiaries as a preventive benefit. Many private insurers have also begun covering it, and some employer health plans include it as part of their wellness benefits. Eligibility generally requires a documented prediabetes diagnosis or blood sugar results in the prediabetes range, verified by a healthcare provider.

Navigating Two Systems at Once

The metabolic health and health insurance conversations don't always speak the same language, and that gap is where a lot of the confusion for people in the prediabetes zone originates. Metabolic health research operates on a long time horizon — thinking in decades, tracking trajectories, valuing early signals. Health insurance operates on plan years, diagnosis codes, coverage criteria, and administrative categories that don't always map cleanly onto the nuanced, continuum-based biology of early metabolic drift.

The Coverage Clarity Spectrum is a useful lens here: some questions — coverage eligibility under the ACA, preventive screening benefits, DPP access — have clear, well-established answers. Others — CGM coverage for prediabetes, the handling of borderline metabolic data in various insurance contexts, the evolving evidence base for non-diabetic CGM use — sit in genuinely contested, actively evolving territory where the honest answer is "it depends, and the landscape is changing."

What remains stable across all of this is the value of asking specific questions: of a clinician about clinical recommendations, of a plan's member services about specific benefit coverage, and of an insurance professional about products that operate outside ACA regulations. The intersection of metabolic health and insurance is not a place where general answers tend to hold for very long — individual plans, individual clinical circumstances, and an evolving regulatory landscape all interact in ways that make direct, specific inquiry more reliable than any general summary can be.